Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio ...

Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of ...
PharmExec

Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of ...

Pre-clinical data supports ECRIs' broad-spectrum attack on the IgE axis, distinct from conventional anti-IgE therapies, ...
PharmExec

Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval

Novartis gains FDA approval for Rhapsido, the first oral BTK inhibitor for Chronic Spontaneous Urticaria, offering new hope ...

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi ...

Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who ...
MedPage Today on MSN

Oral Drug Wins FDA Approval for Chronic Hives

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic ...